Bastyr to undertake echinacea-respiratory tract infection study funded by Madaus AG.
This article was originally published in The Tan Sheet
Executive Summary
BASTYR ECHINACEA AND RESPIRATORY TRACT INFECTIONS $385,000 STUDY is being funded by Cologne, Germany-based company Madaus AG. The 16-month, double-blind, placebo-controlled study will examine the effectiveness of Echinacea purpurea (purple coneflower) in mitigating the frequency and severity of respiratory tract infections as a potential alternative to antibiotics.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning